Quadrant Private Wealth Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Quadrant Private Wealth Management’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.1K	Hold	10,000	–	–	﹤0.01%	175
2026 Q1	$15.8K	Hold	10,000	–	–	﹤0.01%	280
2025 Q4	$16.7K	Hold	10,000	–	–	﹤0.01%	272
2025 Q3	$16.9K	Hold	10,000	–	–	﹤0.01%	251
2025 Q2	$9.07K	Hold	10,000	–	–	﹤0.01%	249
2025 Q1	$4.52K	Hold	10,000	–	–	﹤0.01%	229
2024 Q4	$5.03K	Hold	10,000	–	–	﹤0.01%	242
2024 Q3	$9.05K	Hold	10,000	–	–	﹤0.01%	243
2024 Q2	$9.97K	Sell	10,000 -5,000	-33%	-$5.52K	﹤0.01%	252
2024 Q1	$22.2K	Buy	15,000 +5,000	+50%	+$5.67K	0.01%	236
2023 Q4	$10.9K	Hold	10,000	–	–	﹤0.01%	232
2023 Q3	$11.8K	Hold	10,000	–	–	﹤0.01%	222
2023 Q2	$14.1K	Hold	10,000	–	–	﹤0.01%	246
2023 Q1	$15K	Hold	10,000	–	–	﹤0.01%	247
2022 Q4	$11.7K	Buy	+10,000	New	+$12.6K	﹤0.01%	242
2022 Q2	$16K	Hold	10,000	–	–	0.01%	206
2022 Q1	$15K	Hold	10,000	–	–	0.01%	208
2021 Q4	$25K	Hold	10,000	–	–	0.01%	201
2021 Q3	$25K	Hold	10,000	–	–	0.01%	192
2021 Q2	$29K	Hold	10,000	–	–	0.01%	193
2021 Q1	$24K	Hold	10,000	–	–	0.01%	192
2020 Q4	$18K	Hold	10,000	–	–	0.01%	185
2020 Q3	$9K	Hold	10,000	–	–	﹤0.01%	175
2020 Q2	$9K	Hold	10,000	–	–	0.01%	181
2020 Q1	$8K	Hold	10,000	–	–	0.01%	147
2019 Q4	$9K	Buy	+10,000	New	+$8.33K	0.01%	112
2019 Q3	–	Sell	-10,000	Closed	-$11K	–	113
2019 Q2	$11K	Hold	10,000	–	–	0.01%	105
2019 Q1	$13K	Hold	10,000	–	–	0.01%	104
2018 Q4	$9K	Sell	10,000 -1,430	-13%	-$2.19K	0.01%	96
2018 Q3	$24K	Hold	11,430	–	–	0.02%	99
2018 Q2	$21K	Hold	11,430	–	–	0.02%	99
2018 Q1	$27K	Hold	11,430	–	–	0.04%	86
2017 Q4	$22K	Buy	+11,430	New	+$25K	0.02%	94

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Quadrant Private Wealth Management's LCTX Position: Q2 2026 in Review

Quadrant Private Wealth Management held its Lineage Cell Therapeutics (LCTX) position steady in Q2 2026 at 10,000 shares worth $13.1K. The position accounts for ﹤0.01% of the portfolio, ranked #175.

Quadrant Private Wealth Management first reported a position in LCTX in Q4 2017 and has held it in 33 quarters since. The position peaked at $29K in Q2 2021. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

Quadrant Private Wealth Management held 10,000 shares of Lineage Cell Therapeutics worth $13.1K as of Q2 2026.
Quadrant Private Wealth Management left its Lineage Cell Therapeutics share count unchanged in Q2 2026.
Lineage Cell Therapeutics made up ﹤0.01% of Quadrant Private Wealth Management's portfolio in Q2 2026, its #175 holding.
Quadrant Private Wealth Management first reported a position in Lineage Cell Therapeutics in Q4 2017 and has held it in 33 quarters since.
Quadrant Private Wealth Management's Lineage Cell Therapeutics position peaked at $29K in Q2 2021.
132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Quadrant Private Wealth Management's 13F filing for Q2 2026, filed 30 Jul 2026.